Colleen Kusy Analyst Performance

Senior Research Analyst at Robert W. Baird

Colleen Kusy is a stock analyst at Robert W. Baird in the medical sector, covering 7 publicly traded companies. Over the past year, Colleen Kusy has issued 10 stock ratings, including buy and hold recommendations. While full access to Colleen Kusy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Colleen Kusy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 10 Last 0 Years
Buy Recommendations: 70.00% 7 Buy Ratings
Companies Covered: 7 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	70.0%	7 ratings
Hold	30.0%	3 ratings
Sell	0.0%	0 ratings

Out of 10 total stock ratings issued by Colleen Kusy at Robert W. Baird, the majority (70.0%) have been Buy recommendations, followed by 30.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	7 companies

Colleen Kusy, an analyst at Robert W. Baird, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 7 companies	100.0%

Colleen Kusy of Robert W. Baird specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 5 companies	71.4%
MED - DRUGS 2 companies	28.6%

About Colleen Kusy

Colleen Kusy is a Baird Senior Research Analyst covering Biotechnology. Colleen joined Baird in 2014. Prior to her current role, she spent over six years as a sell-side associate covering biotechnology stocks across a range of therapeutic areas and market caps at Baird. She started her career in Fixed Income Capital Markets at Baird as a business analyst. In 2023, Colleen was named a “Rising Star of Equity Research” by Business Insider. Colleen received a BBA in Finance and a BA in French and Francophone Studies from Villanova University.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
OCUL Ocular Therapeutix	10/3/2025	Boost Price Target	$11.06	$24.00	Outperform
CLYM Climb Bio	8/15/2025	Initiated Coverage	$1.72	$9.00	Outperform
APLS Apellis Pharmaceuticals	7/18/2025	Boost Price Target	$20.04	$50.00	Outperform
NUVL Nuvalent	6/25/2025	Boost Price Target	$77.29	$112.00	Outperform
ELVN Enliven Therapeutics	6/16/2025	Boost Price Target	$21.91	$52.00	Outperform
AGEN Agenus	6/4/2025	Boost Price Target	$5.00	$6.00	Neutral
AGEN Agenus	5/13/2025	Boost Price Target	$3.50	$4.00	Neutral
APLS Apellis Pharmaceuticals	5/8/2025	Lower Price Target	$17.99	$47.00	Outperform
OCS Oculis	3/13/2025	Boost Price Target	$18.84	$41.00	Outperform
AGEN Agenus	3/12/2025	Lower Price Target	$2.05	$3.00	Neutral

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.